Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting), By Product (Reagent, Instrument), By Region and Competition, 2019-2029F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBlood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting), By Product (Reagent, Instrument), By Region and Competition, 2019-2029F
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 2.52 Billion |
| Market Size (2029) | USD 3.45 Billion |
| CAGR (2024-2029) | 5.25% |
| Fastest Growing Segment | Reagent |
| Largest Market | North America |
Market Overview
Global Blood Screening Market
The global prevalence of infectious diseases, including HIV, hepatitis B and C, and syphilis, underscores the significance of rigorous blood screening. Advanced screening technologies aid in the early detection of these infections, preventing their transmission through blood transfusions.
Key Market Drivers
Rising Incidence of Infectious Diseases is Driving the Global Blood Screening Market.
In recent years, the world has witnessed a significant rise in the incidence of infectious diseases, triggering a surge in the demand for advanced diagnostic solutions. One of the critical components in combating the spread of these diseases is efficient blood screening. The global blood screening market has become a vital player in safeguarding public health by ensuring the safety of blood transfusions and donated blood products
Advances in technology have revolutionized blood screening techniques. Nucleic acid testing (NAT), serological testing, and molecular screening methods have become more sensitive and specific, enabling the detection of a broader range of infectious agents with higher accuracy. These innovations have significantly contributed to the market's growth.
Rising Healthcare Expenditure is Driving the Global Blood Screening Market
In recent years, the global healthcare landscape has witnessed a significant rise in expenditure, with a substantial portion allocated to diagnostic services and disease prevention. Among the various segments within the healthcare industry, the blood screening market has experienced substantial growth, propelled by increased healthcare spending. The intersection of advanced technology, rising awareness of blood-borne diseases, and the growing demand for preventive healthcare measures has positioned the blood screening market as a crucial component in the overall healthcare system
Advances in technology have revolutionized blood screening processes. Automated and high-throughput screening methods, including nucleic acid testing (NAT), enzyme immunoassay (EIA), and next-generation sequencing (NGS), have significantly improved the efficiency and accuracy of blood screening. These technological advancements, while enhancing diagnostic capabilities, have also led to increased adoption and contributed to the expansion of the blood screening market.
Key Market Challenges
Global Blood Shortages
The primary challenge faced by the blood screening market is the insufficient availability of safe blood. Many regions around the world struggle with low blood donation rates, leading to a perpetual shortage. This shortage not only affects the ability to meet the demand for blood transfusions but also hampers the efficiency of blood screening processes. Blood shortages are not evenly distributed globally. Some regions face chronic shortages, while others may have a surplus. This geographical imbalance creates challenges for the blood screening market to establish standardized processes and technologies that can be universally applied. Economic factors, coupled with societal beliefs and cultural practices, contribute to the reluctance of individuals to donate blood. Issues such as fear, misinformation, and lack of awareness often deter potential donors, exacerbating the global blood shortage crisis. The blood screening market operates within a complex regulatory framework to ensure the safety and quality of blood products. Adhering to evolving regulations can be challenging for both established and emerging players in the industry, impacting their ability to innovate and adapt swiftly. In certain regions, technological and infrastructure gaps pose challenges for implementing advanced blood screening technologies. Limited access to cutting-edge screening methods and equipment can compromise the efficacy of the blood screening process.
Key Market Trends
Technological Advancements
In the realm of healthcare, the Global Blood Screening Market is experiencing a transformative wave driven by unprecedented technological advancements. The integration of cutting-edge technologies is enhancing the efficiency, accuracy, and scope of blood screening processes, thereby revolutionizing healthcare practices worldwide
Artificial intelligence and machine learning are making significant strides in healthcare, and blood screening is no exception. These technologies can analyze vast amounts of data, identify patterns, and enhance the interpretation of screening results. AI-driven algorithms can improve the accuracy of diagnoses, predict potential health risks, and optimize treatment strategies. Integrating AI and ML into blood screening processes not only improves efficiency but also contributes to more personalized and precise healthcare solutions.
Segmental Insights
Product Insights
Based
Regional Insights
North America emerged as the dominated region in the global blood screening market in 2023, holding the largest market share in terms of value. North America has been quick to adopt and implement cutting-edge technologies in blood screening. The region's laboratories and diagnostic centers have embraced automation, high-throughput screening, and advanced molecular techniques, enhancing the efficiency and accuracy of blood screening processes. The integration of next-generation sequencing, polymerase chain reaction (PCR), and other molecular diagnostic tools has allowed for the early detection of infectious diseases, genetic disorders, and other health conditions. The region's well-developed healthcare infrastructure has played a crucial role in propelling North America to the forefront of the blood screening market. The presence of state-of-the-art laboratories, research facilities, and a network of well-established healthcare providers has facilitated seamless collaboration between industry stakeholders. This infrastructure not only supports routine blood screenings but also enables swift responses to emerging health threats, reinforcing the region's dominance in global blood screening.
Recent Developments
- In March 2023, Abbott obtained clearance from theU.S. Food and Drug Administration (FDA) for a laboratory blood test designed toassess mild traumatic brain injuries (TBIs), commonly known as concussions.This marks the first commercially accessible lab-based test for such injuries.The test, utilizing Abbott's Alinity i laboratory tool, will soon be accessiblein hospitals throughout the United States, providing clinicians with a timelyand effective means to evaluate individuals with mild traumatic brain injuries.
- In May 2023, Siemens Healthcare launched the Atellica HEMA 570 and 580,advanced hematology analyzers with intuitive interfaces. These analyzersfacilitate seamless connectivity with multiple devices, eliminating workflowobstacles and ensuring efficient processing.
Key Market Players
- AbbottLaboratories Inc.
- Danaher Corporation (Beckman Coulter)
- Becton Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Hoffman-La Roche Ltd.
- Grifols, S.A.
- Ortho-Clinical Diagnostics, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
- SOFINA s.a (Biomerieux)
| By Technology | By Product | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy